Purpose of Review
Comprehensive lifestyle programs are cornerstones of obesity management, but clinician referrals may be limited by program availability. Commercial weight loss programs may be an alternative, but clinicians may be unaware of their efficacy and safety. This review describes the evidence for commercial programs, particularly 12-month weight loss, among individuals with obesity.
Several programs are concordant with evidence-based recommendations (i.e., lower-calorie diet, increased physical activity, and behavioral strategies). Among the guideline-concordant programs, National Diabetes Prevention Program, WW, Jenny Craig, Medifast, and OPTIFAST have demonstrated 12-month weight loss efficacy and safety. While other programs show promise, more evidence is needed before clinician referral may be recommended.
Clinical practice guidelines support referrals to commercial weight loss programs that have peer-reviewed evidence to support their efficacy and safety. Clinicians should consider the available evidence, patient preference, and cost when considering referrals to these programs for weight management.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance
Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2013;2014(129):S102–38. https://doi.org/10.1161/01.cir.0000437739.71477.ee.
Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320:1163–71. https://doi.org/10.1001/jama.2018.13022.
Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl 3):1–203. https://doi.org/10.4158/EP161365.GL.
Brauer P, Gorber SC, Shaw E, Singh H, Bell N, Shane ARE, et al. Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care. CMAJ. 2015;187:184–95. https://doi.org/10.1503/cmaj.140887.
Bloom B, Mehta AK, Clark JM, Gudzune KA. Guideline-concordant weight-loss programs in an urban area are uncommon and difficult to identify through the Internet. Obesity. 2016;24:583–8. https://doi.org/10.1002/oby.21403.
Key National DPP Milestones. Accessed at https://www.cdc.gov/diabetes/prevention/milestones.htm on March 30, 2020.
Medicare Diabetes Prevention Program (MDPP). Accessed at https://coveragetoolkit.org/medicare-advantage/mdpp-final-rule/ on March 30, 2020.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. https://doi.org/10.1056/NEJMoa012512.
Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86. https://doi.org/10.1016/S0140-6736(09)61457-4.
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3:866–75. https://doi.org/10.1016/S2213-8587(15)00291-0.
Gudzune KA, Doshi RS, Mehta AK, Chaudhry ZW, Jacobs DK, Vakil RM, et al. Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med. 2015;162:501–12. https://doi.org/10.7326/M14-2238.
Gudzune KA, Clark JM. Commercial weight loss programs. In: Wadden TA, Bray GE, editors. Handbook of Obesity Treatment. 2nd ed. New York: Guilford Press; 2018. p. 480–91.
Johnston BC, Kanters S, Bandayrel K, Wu P, Naji F, Siemieniuk RA, et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA. 2014;312:923–33. https://doi.org/10.1001/jama.2014.10397.
Jolly K, Lewis A, Beach J, Denley J, Adab P, Deeks JJ, et al. Comparison of range of commercial or primary care led weight reduction programmes with minimal intervention control for weight loss in obesity: lighten up randomised controlled trial. BMJ. 2011;343:d6500. https://doi.org/10.1136/bmj.d6500.
Gorin AA, Lenz EM, Cornelius T, Huedo-Medina T, Wojtanowski AC, Foster GD. Randomized controlled trial examining the ripple effect of a nationally available weight management program on untreated spouses. Obesity. 2018;26:499–504. https://doi.org/10.1002/oby.22098.
• Thomas JG, Raynor HA, Bond DS, Luke AK, Cardoso CC, Foster GD, et al. Weight loss in Weight Watchers online with and without an activity tracking device compared to control: a randomized trial. Obesity. 2017;25:1014–21. https://doi.org/10.1002/oby.21846First RCT reporting outcomes for Weight Watchers Online program.
• Ahern AL, Wheeler GM, Aveyard P, Boyland EJ, Halford JCG, Mander AP, et al. Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial. Lancet. 2017;389:2214–25. https://doi.org/10.1016/S0140-6736(17)30647-5RCT examining duration of participation in WW and how it influences long-term weight loss outcomes – suggests that continued engagement with WW to 52 weeks is beneficial for weight loss and weight loss maintenance, which may be a key counseling point for clinicians.
Yancy WS Jr, Shaw PA, Wesby L, Hilbert V, Yang L, Zhu J, et al. Financial incentive strategies for maintenance of weight loss: results from an internet-based randomized controlled trial. Nutr Diabetes. 2018;8:33. https://doi.org/10.1038/s41387-018-0036-y.
Yancy WS Jr, Shaw PA, Reale C, Hilbert V, Yan J, Zhu J, et al. Effect of escalating financial incentive rewards on maintenance of weight loss: a randomized clinical trial. JAMA Netw Open. 2019;2:e1914393. https://doi.org/10.1001/jamanetworkopen.2019.14393.
Marrero DG, Palmer KN, Phillips EO, Miller-Kovach K, Foster GD, Saha CK. Comparison of commercial and self-initiated weight loss programs in people with prediabetes: a randomized control trial. Am J Public Health. 2016;106:949–56. https://doi.org/10.2105/AJPH.2015.303035.
Palmer KNB, Sasha C, Phillips EO, Krish A, Foster GD, Finkelstein E, et al. The two-year outcomes and cost-effectiveness of a commercial weight loss program for the prevention of type 2 diabetes among people with prediabetes. Endocrinol Diabetes Obes. 2018;1:6. https://doi.org/10.31532/EndocrinolDiabetesObes.1.1.005.
Rock CL, Flatt SW, Pakiz B, Taylor KS, Leone AF, Brelje K, et al. Weight loss, glycemic control, and cardiovascular disease risk factors in response to differential diet composition in a weight loss program in type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014;37:1573–80. https://doi.org/10.2337/dc13-2900.
Chaudhry ZW, Doshi RS, Mehta AK, Jacobs DK, Vakil RM, Lee CJ, et al. A systematic review of commercial weight loss programmes’ effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus. Obes Rev. 2016;17:758–69. https://doi.org/10.1111/obr.12423.
Donnelly JE, Goetz J, Gibson C, Sullivan DK, Lee R, Smith BK, et al. Equivalent weight loss for weight management programs delivered by phone and clinic. Obesity. 2013;21:1951–9. https://doi.org/10.1002/oby.20334.
Shikany JM, Thomas AS, Beasley TM, Lewis CE, Allison DB. Randomized controlled trial of the Medifast 5 & 1 plan for weight loss. Int J Obes. 2013;37:1571–8. https://doi.org/10.1038/ijo.2013.43.
Moldovan CP, Weldon AJ, Daher NS, Schneider LE, Bellinger DL, Berk LS, et al. Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings. Obesity. 2016;24:2344–50. https://doi.org/10.1002/oby.21649.
Beavers KM, Nesbit BA, Kiel JR, Sheedy JL, Arterburn LM, Collins AE, et al. Effect of an energy-restricted, nutritionally complete, higher protein meal plan on body composition and mobility in older adults with obesity: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2019;74:929–35. https://doi.org/10.1093/gerona/gly146.
• Ard JD, Lewis KH, Rothberg A, Auriemma A, Coburn SL, Cohen SS, et al. Effectiveness of a total meal replacement program (OPTIFAST Program) on weight loss: results from the OPTIWIN study. Obesity. 2019;27:22–9. https://doi.org/10.1002/oby.22303Well-designed RCT demonstrating the efficacy of OPTIFAST.
Allen JK, Stephens J, Dennison Himmelfarb CR, Stewart KJ, Hauck S. Randomized controlled pilot study testing use of smartphone technology for obesity treatment. J Obes. 2013;2013:151597. https://doi.org/10.1155/2013/151597.
Laing BY, Mangione CM, Tseng CH, Leng M, Vaisberg E, Mahida M, et al. Effectiveness of a smartphone application for weight loss compared with usual care in overweight primary care patients: a randomized, controlled trial. Ann Intern Med. 2014;161(10 Suppl):S5–12. https://doi.org/10.7326/M13-3005.
Jospe MR, Roy M, Brown RC, Williams SM, Osborne HR, Meredith-Jones KA, et al. The effect of different types of monitoring strategies on weight loss: a randomized controlled trial. Obesity. 2017;25:1490–8. https://doi.org/10.1002/oby.21898.
Toro-Ramos T, Lee DH, Kim Y, Michaelides A, Oh TJ, Kim KM, et al. Effectiveness of a smartphone application for the management of metabolic syndrome components focusing on weight loss: a preliminary study. Metab Syndr Relat Disord. 2017;15:465–73. https://doi.org/10.1089/met.2017.0062.
Chin SO, Keum C, Woo J, Park J, Choi HJ, Woo J, et al. Successful weight reduction and maintenance by using a smartphone application in those with overweight and obesity. Sci Rep. 2016;6:34563. https://doi.org/10.1038/srep34563.
Michaelides A, Raby C, Wood M, Farr K, Toro-Ramos T. Weight loss efficacy of a novel mobile Diabetes Prevention Program delivery platform with human coaching. BMJ Open Diabetes Res Care. 2016;4:e000264. https://doi.org/10.1136/bmjdrc-2016-000264.
Michaelides A, Major J, Pienkosz E Jr, Wood M, Kim Y, Toro-Ramos T. Usefulness of a novel mobile Diabetes Prevention Program delivery platform with human coaching: 65-week observational follow-up. JMIR Mhealth Uhealth. 2018;6:e93. https://doi.org/10.2196/mhealth.9161.
Hildebrandt T, Michaelides A, Mackinnon D, Greif R, DeBar L, Sysko R. Randomized controlled trial comparing smartphone assisted versus traditional guided self-help for adults with binge eating. Int J Eat Disord. 2017;50:1313–22. https://doi.org/10.1002/eat.22781.
Sepah SC, Jiang L, Peters AL. Long-term outcomes of a web-based Diabetes Prevention Program: 2-year results of a single-arm longitudinal study. J Med Internet Res. 2015;17:e92. https://doi.org/10.2196/jmir.4052.
Sepah SC, Jiang L, Ellis RJ, McDermott K, Peters AL. Engagement and outcomes in a digital Diabetes Prevention Program: 3-year update. BMJ Open Diabetes Res Care. 2017;5:e000422. https://doi.org/10.1136/bmjdrc-2017-000422.
Castro Sweet CM, Chiguluri V, Gumpina R, Abbott P, Madero EN, Payne M, et al. Outcomes of a Digital Health Program With Human Coaching for Diabetes Risk Reduction in a Medicare Population. J Aging Health. 2018;30:692–710. https://doi.org/10.1177/0898264316688791.
Mitchell NS, Dickinson LM, Kempe A, Tsai AG. Determining the effectiveness of Take Off Pounds Sensibly (TOPS), a nationally available nonprofit weight loss program. Obesity (Silver Spring). 2011;19(3):568–73. https://doi.org/10.1038/oby.2010.202.
Community Preventive Services Task Force. Combined diet and physical activity promotion programs for prevention of diabetes: Community Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015;163:465–8. https://doi.org/10.7326/M15-1029.
Program Eligibility. Accessed at https://www.cdc.gov/diabetes/prevention/program-eligibility.html on March 30, 2020.
Finkelstein EA, Kruger E. Meta- and cost-effectiveness analysis of commercial weight loss strategies. Obesity. 2014;22:1942–51. https://doi.org/10.1002/oby.20824.
Finkelstein EA, Verghese NR. Incremental cost-effectiveness of evidence-based non-surgical weight loss strategies. Clin Obes. 2019;9:e12294. https://doi.org/10.1111/cob.12294.
IBISWorld. Weight loss services in the U.S. industry market research report 2019. Accessed at http://www.ibisworld.com. Accessed March 11, 2020.
Arterburn LM, Coleman CD, Kiel J, Kelley K, Mantilla L, Frye N, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obes Sci Pract. 2019;5:3–14. https://doi.org/10.1002/osp4.312.
Heymsfield SB. Meal replacements and energy balance. Physiol Behav. 2010;100(1):90–4. https://doi.org/10.1016/j.physbeh.2010.02.010.
Mehta AK, Doshi RS, Chaudhry ZW, Jacobs DK, Vakil RM, Lee CJ, et al. Benefits of commercial weight-loss programs on blood pressure and lipids: a systematic review. Prev Med. 2016;90:86–99. https://doi.org/10.1016/j.ypmed.2016.06.028.
This work received no direct funding support. ML is supported by a training grant from the National Heart, Lung and Blood Institute (T32HL007180-44). KAG was supported from a grant from the National Institute for Mental Health (P50MH115842). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Conflict of Interest
KAG is a paid consultant for Eli Lilly Inc.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Obesity Treatment
Rights and permissions
About this article
Cite this article
Laudenslager, M., Chaudhry, Z.W., Rajagopal, S. et al. Commercial Weight Loss Programs in the Management of Obesity: an Update. Curr Obes Rep 10, 90–99 (2021). https://doi.org/10.1007/s13679-021-00428-y
- Weight reduction programs
- Treatment outcome